Daiichi Sankyo Expands Oncology Portfolio with Key ASCO Data
Event summary
- Daiichi Sankyo presented over 25 abstracts at ASCO 2026, highlighting progress across its oncology portfolio.
- New data from DESTINY-Breast05 and DESTINY-Gastric04 trials supported recent U.S. and Asian regulatory approvals for Enhertu.
- TROPION-Breast02 data led to the first U.S. approval of Datroway for metastatic triple-negative breast cancer.
- Trials-in-progress include new medicines developed through the Breakthrough Generating Technology (BGT) platform.
The big picture
Daiichi Sankyo's ASCO 2026 updates underscore its leadership in antibody-drug conjugate (ADC) technology, particularly in HER2-targeted therapies. The company's ability to translate clinical data into regulatory wins positions it as a key player in precision oncology. The BGT platform represents a strategic bet on accelerating drug discovery, but its success will depend on consistent execution across multiple cancer indications.
What we're watching
- Regulatory Momentum
- Whether Daiichi Sankyo can sustain the pace of regulatory approvals for its ADC portfolio.
- Pipeline Execution
- The pace at which the BGT platform delivers new clinical candidates.
- Commercial Strategy
- How Daiichi Sankyo and AstraZeneca will position Enhertu and Datroway against competitors.
Related topics